Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2001 1
2004 2
2005 1
2006 2
2007 1
2009 1
2010 1
2014 2
2015 3
2016 4
2017 1
2020 3
2021 4
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: ramdave s. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: ramdave s. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30. Lancet Oncol. 2024. PMID: 38043558 Clinical Trial.
68 Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer.
Davies A, Foo M, Gan CL, Kourambas J, Redgrave N, Donnellan S, Appu S, Williams S, Coleman A, Segelov E, Bradley J, Soo G, Ramdave S, Kwan EM, Azad AA. Davies A, et al. Among authors: ramdave s. Asia Pac J Clin Oncol. 2022 Oct;18(5):e204-e210. doi: 10.1111/ajco.13595. Epub 2021 Jun 23. Asia Pac J Clin Oncol. 2022. PMID: 34161628
No needle to fear: An approach to needle phobic patients.
Hudswell L, Pinson J, Ramdave S, Bradley J. Hudswell L, et al. Among authors: ramdave s. Asia Ocean J Nucl Med Biol. 2020 Spring;8(2):160-163. doi: 10.22038/AOJNMB.2020.45184.1304. Asia Ocean J Nucl Med Biol. 2020. PMID: 32715008 Free PMC article.
68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer.
Xue AL, Kalapara AA, Ballok ZE, Levy SM, Sivaratnam D, Ryan A, Ramdave S, O'Sullivan R, Moon D, Grummet JP, Frydenberg M. Xue AL, et al. Among authors: ramdave s. J Urol. 2022 Feb;207(2):341-349. doi: 10.1097/JU.0000000000002254. Epub 2021 Sep 21. J Urol. 2022. PMID: 34546815
Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology.
Kalapara AA, Ballok ZE, Ramdave S, O'Sullivan R, Ryan A, Konety B, Grummet JP, Frydenberg M. Kalapara AA, et al. Among authors: ramdave s. Eur Urol Oncol. 2022 Jun;5(3):314-320. doi: 10.1016/j.euo.2021.02.006. Epub 2021 Mar 23. Eur Urol Oncol. 2022. PMID: 33741337
28 results